Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal Psychophysiological Assessment Reveals Gastric but Not Cardiac Interoception Deficits in Disorders of Gut-Brain Interaction.

Psychophysiology·2025
Same author

Retraction Note: Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TGF-beta1 downregulation.

European review for medical and pharmacological sciences·2025
Same author

Clinical outcomes and complications of tracheal resection and anastomosis in dogs and cats: 20 cases (2009-2022).

The Journal of small animal practice·2025
Same author

Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients.

Journal of endocrinological investigation·2023
Same author

Short-term outcome and complications following cutaneous reconstruction using cranial superficial epigastric axial pattern flaps in dogs: six cases (2008-2022).

The Journal of small animal practice·2023
Same author

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

ESMO open·2022
Same journal

Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Novel approaches to liquid biopsy in pancreatic cancer.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

GLP-1 receptor agonists in pediatric obesity.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

An unusual gastric mass in a patient with human immunodeficiency virus infection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Fibrate therapy in primary sclerosing cholangitis: missing data on lipids, interactions, and cancer risk.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Pharmacovigilance of drug-induced microscopic colitis: time to consider exposure duration and dechallenge completeness.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Polycystic liver diseases.

P Onori1, A Franchitto, R Mancinelli

  • 1Experimental Medicine, University of L'Aquila, L'Aquila, Italy.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|February 9, 2010
PubMed
Summary
This summary is machine-generated.

Polycystic liver diseases (PCLDs) involve genetic defects causing liver cysts. Primary cilia abnormalities and estrogen sensitivity in PCLD cells offer potential therapeutic targets for cyst progression.

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Related Experiment Videos

Last Updated: Jun 16, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

Area of Science:

  • Hepatology
  • Genetics
  • Cell Biology

Background:

  • Polycystic liver diseases (PCLDs) are genetic disorders characterized by progressive liver cyst development.
  • Cysts can be isolated or associated with polycystic kidney disease, often more severe in women.
  • Cholangiocytes, the cells lining bile ducts, possess primary cilia crucial for sensing mechanical forces and regulating cellular processes.

Purpose of the Study:

  • To explore the role of primary cilia dysfunction in PCLD pathogenesis.
  • To investigate the influence of estrogens and growth factors on PCLD cyst epithelium.
  • To identify potential therapeutic targets for modulating PCLD progression.

Main Methods:

  • Review of the molecular mechanisms underlying PCLD.
  • Analysis of the function of primary cilia in cholangiocytes.
  • Examination of the role of estrogens and growth factors in cystic epithelium.

Main Results:

  • Absence of polycystin proteins in primary cilia is linked to cyst formation, increased proliferation, apoptosis, fluid secretion, and altered cell polarity.
  • Estrogens and growth factors like NGF, IGF1, FSH, and VEGF can regulate the proliferative and secretive activities of PCLD cystic epithelium.
  • Primary cilia abnormalities and estrogen sensitivity in PCLD cystic epithelium are key morpho-functional features.

Conclusions:

  • Dysfunctional primary cilia are central to PCLD development.
  • The PCLD cystic epithelium exhibits sensitivity to estrogens and growth factors.
  • Modulating these pathways presents a promising strategy for future PCLD treatments.